References
- Wang C , HorbyPW, HaydenFG, GaoGF. A novel coronavirus outbreak of global health concern. Lancet, 395(10223), 470–473 (2020).
- Zhou P , YangXL, WangXGet al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273 (2020).
- WHO . Update 49 - SARS case fatality ratio, incubation period. (2020) https://www.who.int/csr/sars/archive/2003_05_07a/en/ ( accessed on 29 Jun 2021).
- Yang ZY , KongWP, HuangYet al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature, 428(6982), 561–564 (2004).
- de Wit E , van DoremalenN, FalzaranoD, MunsterVJ. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol., 14(8), 523–534 (2016).
- Chen Y , LiuQ, GuoD. Emerging coronaviruses: genome structure, replication, and pathogenesis. J. Med. Virol., 92(4), 418–423 (2020).
- Worldometer . COVID-19 coronavirus pandemic. (2021). https://www.worldometers.info/coronavirus/
- Roser M , RitchieH, Ortiz-OspinaE, HasellJ. Coronavirus disease (COVID-19) – statistics and research. (2021) https://ourworldindata.org/coronavirus
- Lu R , ZhaoX, LiJet al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 395(10224), 565–574 (2020).
- Xu Z , ShiL, WangYet al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med., 8(4), 420–422 (2020).
- Schwartz DA , GrahamAL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses, 12(2), 194 (2020).
- Braciale TJ , SunJ, KimTS. Regulating the adaptive immune response to respiratory virus infection. Nat. Rev. Immunol., 12(4), 295–305 (2012).
- Mehata AK , ViswanadhMK, PriyaV, MuthuMS. Dendritic cell-targeted theranostic nanomedicine: advanced cancer nanotechnology for diagnosis and therapy. Nanomedicine (London), 15(10), 947–949 (2020).
- Zu ZY , JiangMD, XuPPet al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology, 200490 (2020).
- Letko M , MarziA, MunsterV. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol., 5(4), 562–569 (2020).
- Liu X , ShiY, LiPet al. Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients. Clin. Diagn. Lab. Immunol., 11(1), 227–228 (2004).
- Masters PS . The molecular biology of coronaviruses. Adv. Virus Res., 66, 193–292 (2006).
- Chan JF , KokKH, ZhuZet al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect., 9(1), 221–236 (2020).
- Fehr AR , PerlmanS. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol., 1282, 1–23 (2015).
- Prompetchara E , KetloyC, PalagaT. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac. J. Allergy Immunol., 38(1), 1–9 (2020).
- Zolfaghari Emameh R , NosratiH, EftekhariM, FalakR, KhoshmirsafaM. Expansion of single cell transcriptomics data of SARS-CoV infection in human bronchial epithelial cells to COVID-19. Biol. Proced. Online, 22, 16 (2020).
- Schenkel JM , FraserKA, BeuraLK, PaukenKE, VezysV, MasopustD. T-cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science, 346(6205), 98–101 (2014).
- Paludan SR , BowieAG, HoranKA, FitzgeraldKA. Recognition of herpesviruses by the innate immune system. Nat. Rev. Immunol., 11(2), 143–154 (2011).
- Iwasaki A , PillaiPS. Innate immunity to influenza virus infection. Nat. Rev. Immunol., 14(5), 315–328 (2014).
- Akira S , UematsuS, TakeuchiO. Pathogen recognition and innate immunity. Cell, 124(4), 783–801 (2006).
- Kawai T , AkiraS. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol., 21(4), 317–337 (2009).
- Azkur AK , AkdisM, AzkurDet al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy, 75(7), 1564–1581 (2020).
- Golonka RM , SahaP, YeohBSet al. Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease. Physiol. Genomics, 52(5), 217–221 (2020).
- Zhou Z , RenL, ZhangLet al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe, 27(6), 883–890.e882 (2020).
- Merad M , MartinJC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol., 20(6), 355–362 (2020).
- Du SQ , YuanW. Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis. J. Med. Virol., 92(9), 1615–1628 (2020).
- Felsenstein S , HerbertJA, McNamaraPS, HedrichCM. COVID-19: immunology and treatment options. Clin. Immunol., 215, 108448 (2020).
- Wang F , HouH, LuoYet al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight, 5(10), e137799 (2020).
- Iwasaki A , MedzhitovR. Regulation of adaptive immunity by the innate immune system. Science, 327(5963), 291–295 (2010).
- Mirtaleb MS , MirtalebAH, NosratiH, HeshmatniaJ, FalakR, ZolfaghariEmameh R. Potential therapeutic agents to COVID-19: an update review on antiviral therapy, immunotherapy, and cell therapy. Biomed. Pharmacother., 138, 111518 (2021).
- Lindsley AW , SchwartzJT, RothenbergME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J. Allergy Clin. Immunol., 146(1), 1–7 (2020).
- Prete M , FavoinoE, CatacchioG, RacanelliV, PerosaF. SARS-CoV-2 inflammatory syndrome. clinical features and rationale for immunological treatment. Int. J. Mol. Sci., 21(9), (2020).
- Henrickson SE . Learning from our immunological history: what can SARS-CoV teach us about SARS-CoV-2?Sci. Immunol., 5(46), eabb8618 (2020).
- Walls AC , ParkYJ, TortoriciMA, WallA, McGuireAT, VeeslerD. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181(2), 281–292.e286 (2020).
- Zhang H , PenningerJM, LiY, ZhongN, SlutskyAS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med., 46(4), 586–590 (2020).
- Wan Y , ShangJ, GrahamR, BaricRS, LiF. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol., 94(7), e00127–20 (2020).
- Tian X , LiC, HuangAet al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect., 9(1), 382–385 (2020).
- Zheng M , SongL. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell Mol. Immunol., 17(5), 536–538 (2020).
- Hoffmann M , Kleine-WeberH, SchroederSet al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2), 271–280.e278 (2020).
- Xia S , ZhuY, LiuMet al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol. Immunol., 17(7), 765–767 (2020).
- Inoue Y , TanakaN, TanakaYet al. Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J. Virol., 81(16), 8722–8729 (2007).
- Wang H , YangP, LiuKet al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res., 18(2), 290–301 (2008).
- Neveu G , Ziv-AvA, Barouch-BentovR, BerkermanE, MulhollandJ, EinavS. AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J. Virol., 89(8), 4387–4404 (2015).
- Richardson P , GriffinI, TuckerCet al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet, 395(10223), e30–e31 (2020).
- Savarino A , BoelaertJR, CassoneA, MajoriG, CaudaR. Effects of chloroquine on viral infections: an old drug against today’s diseases?Lancet Infect. Dis., 3(11), 722–727 (2003).
- Martinez MA . Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob. Agents Chemother., 64(5), e00399–20 (2020).
- Gordon CJ , TchesnokovEP, FengJY, PorterDP, GötteM. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem., 295(15), 4773–4779 (2020).
- Wang M , CaoR, ZhangLet al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 30(3), 269–271 (2020).
- Holshue ML , DeBoltC, LindquistSet al. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med., 382(10), 929–936 (2020).
- Li G , DeClercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov., 19(3), 149–150 (2020).
- Morse JS , LalondeT, XuS, LiuWR. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem., 21(5), 730–738 (2020).
- Risitano AM , MastellosDC, Huber-LangMet al. Complement as a target in COVID-19? Nat. Rev. Immunol., 20(6), 343–344 (2020).
- Gralinski LE , SheahanTP, MorrisonTEet al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio., 9(5), e01753-18 (2018).
- Mastellos DC , RicklinD, LambrisJD. Clinical promise of next-generation complement therapeutics. Nat. Rev. Drug Discov., 18(9), 707–729 (2019).
- Mastaglio S , RuggeriA, RisitanoAMet al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin. Immunol., 215, 108450 (2020).
- Cugno M , MeroniPL, GualtierottiRet al. Complement activation in patients with COVID-19: a novel therapeutic target. J. Allergy Clin. Immunol., 146(1), 215–217 (2020).
- Zilow G , JokaT, ObertackeU, RotherU, KirschfinkM. Generation of anaphylatoxin C3a in plasma and bronchoalveolar lavage fluid in trauma patients at risk for the adult respiratory distress syndrome. Crit. Care Med., 20(4), 468–473 (1992).
- Gao T , HuM, ZhangXet al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. MedRxiv. doi: https://doi.org/10.1101/2020.03.29.20041962 (2020) ( Epub ahead of print).
- Magro C , MulveyJJ, BerlinDet al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl. Res., 220, 1–13 (2020).
- Zhou G , ZhaoQ. Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2. Int. J. Biol. Sci., 16(10), 1718–1723 (2020).
- Li S , BouchyS, PenninckxSet al. Antibody-functionalized gold nanoparticles as tumor-targeting radiosensitizers for proton therapy. Nanomedicine (London), 14(3), 317–333 (2019).
- Gagliani N , AmezcuaVesely MC, IsepponAet al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature, 523(7559), 221–225 (2015).
- Bedoya SK , LamB, LauK, LarkinJ3rd. Th17 cells in immunity and autoimmunity. Clin. Dev. Immunol., 2013, 986789 (2013).
- Li W , ZhangX, YangYet al. Recognition of conserved antigens by Th17 cells provides broad protection against pulmonary Haemophilus influenzae infection. Proc. Natl Acad. Sci. USA, 115(30), E7149–e7157 (2018).
- Antalis E , SpathisA, KottaridiCet al. Th17 serum cytokines in relation to laboratory-confirmed respiratory viral infection: a pilot study. J. Med. Virol., 91(6), 963–971 (2019).
- Li C , YangP, SunYet al. IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus. Cell Res., 22(3), 528–538 (2012).
- Faure E , PoissyJ, GoffardAet al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS ONE, 9(2), e88716 (2014).
- Bermejo-Martin JF , Ortizde Lejarazu R, PumarolaTet al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit. Care., 13(6), R201 (2009).
- Wu D , YangXO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J. Microbiol. Immunol. Infect., 53(3), 368–370 (2020).
- Widjaja I , WangC, van HaperenRet al. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg. Microbes Infect., 8(1), 516–530 (2019).
- Goo J , JeongY, ParkYSet al. Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein. Virus Res., 278, 197863 (2020).
- Zeng LP , GeXY, PengCet al. Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Sci. China Life Sci., 60(12), 1399–1402 (2017).
- Shah M , AhmadB, ChoiS, WooHG. Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization. Comput. Struct. Biotechnol. J., 18, 3402–3414 (2020).
- Cohen J . New coronavirus threat galvanizes scientists. Science, 367(6477), 492–493 (2020).
- Atyeo C , SleinMD, FischingerSet al. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight., 6(1), e143129 (2021).
- Sheppard M , LaskouF, StapletonPP, HadaviS, DasguptaB. Tocilizumab (Actemra). Hum. Vaccin. Immunother., 13(9), 1972–1988 (2017).
- Scott LJ . Tocilizumab: a review in rheumatoid arthritis. Drugs, 77(17), 1865–1879 (2017).
- Xu X , HanM, LiTet al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl Acad. Sci. USA, 117(20), 10970–10975 (2020).
- Chinese Clinical Trial Registry . A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). (2021). http://www.chictr.org.cn/showprojen.aspx?proj=49409
- Kashour T , TleyjehIM. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – author’s reply. Clin. Microbiol. Infect., 27(2), 215–227 (2021).
- Jiang S , HillyerC, DuL. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol., 41(5), 355–359 (2020).
- Shanmugaraj B , SiriwattananonK, WangkanontK, PhoolcharoenW. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for coronavirus disease-19 (COVID-19). Asian Pac. J. Allergy Immunol., 38(1), 10–18 (2020).
- Tsioris K , GuptaNT, OgunniyiAOet al. Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing. Integr. Biol. (Cambridge)., 7(12), 1587–1597 (2015).
- Boskovic M , MigoW, LikicR. SARS-CoV-2 mutations: a strain on efficacy of neutralizing monoclonal antibodies?Br. J. Clin. Pharmacol. doi: https://doi.org/10.1111/bcp.14849 (2021) ( Epub ahead of print).
- Greaney AJ , LoesAN, CrawfordKHDet al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe, 29(3), 463–476.e466 (2021).
- Guo RF , WardPA. Role of C5a in inflammatory responses. Annu. Rev. Immunol., 23, 821–852 (2005).
- Philippidis A . COVID-19: top 60 drug treatments in development: The biopharma industry is ramping up the development of dozens of potential drug therapies and clinical testing in an all-hands effort to combat the pandemic. Genetic Engineeri. Biotechnol. News, 40(4), 10–13 (2020).
- Chen L , XiongJ, BaoL, ShiY. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis., 20(4), 398–400 (2020).
- A phase III study to investigate a vaccine against COVID-19. ISRCTN89951424 (2020). https://doi.org/10.1186/ISRCTN89951424
- Hung IF , ToKK, LeeCKet al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis., 52(4), 447–456 (2011).
- Hung IFN , ToKKW, LeeCKet al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest, 144(2), 464–473 (2013).
- Mair-Jenkins J , Saavedra-CamposM, BaillieJKet al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis., 211(1), 80–90 (2015).
- Schoofs T , KleinF, BraunschweigMet al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science, 352(6288), 997–1001 (2016).
- Lu CL , MurakowskiDK, BournazosSet al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science, 352(6288), 1001–1004 (2016).
- World Health Organization . Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, 25 January 2020. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf
- Shen C , WangZ, ZhaoFet al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA, 323(16), 1582–1589 (2020).
- Duan K , LiuB, LiCet al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad. Sci. USA, 117(17), 9490–9496 (2020).
- Maguire G . Stem cells, part of the innate and adaptive immune systems, as an antimicrobial for coronavirus COVID-19. (2020). https://drgregmaguire.org/2020/02/23/stem-cells-part-of-the-innate-and-adaptive-immune-systems-as-an-antimicrobial-for-coronavirus-covid-19/
- Wood WA , KrishnamurthyJ, MitinNet al. Chemotherapy and stem cell transplantation increase p16(INK4a) expression, a biomarker of T-cell aging. EBioMedicine, 11, 227–238 (2016).
- Wu X , DaoThi VL, HuangYet al. Intrinsic immunity shapes viral resistance of stem cells. Cell, 172(3), 423–438.e425 (2018).
- Amanat F , KrammerF. SARS-CoV-2 vaccines: status report. Immunity, 52(4), 583–589 (2020).
- Liu C , ZhouQ, LiYet al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent. Sci., 6(3), 315–331 (2020).
- Chen WH , StrychU, HotezPJ, BottazziME. The SARS-CoV-2 vaccine pipeline: an overview. Curr. Trop. Med. Rep.(2020) (Epub ahead of print).
- AminJafari A , GhasemiS. The possible of immunotherapy for COVID-19: a systematic review. Int. Immunopharmacol., 83, 106455 (2020).
- Ou X , LiuY, LeiXet al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun., 11(1), 1620 (2020).
- Wrapp D , WangN, CorbettKSet al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367(6483), 1260–1263 (2020).
- Lucchese G . Epitopes for a 2019-nCoV vaccine. Cell Mol. Immunol., 17(5), 539–540 (2020).
- Jonathan Corum DG , WeeSui-Lee, ZimmerCarl. Coronavirus vaccine tracker. (2020) https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
- World Health Organization . DRAFT landscape of COVID-19 candidate vaccines. (2021). https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
- Chinese Clinical Trial Registry . A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19). (2020) http://www.chictr.org.cn/showprojen.aspx?proj=48992
- The Brigham and Women’s Hospital, Inc . US20050282154 (2005).
- University of Massachusetts UMass . US20050069869 (2008).
- University of Hong Kong HKU . US20060110758 (2006).
- Novel Coronavirus@jnjnews . https://www.jnj.com/coronavirus/prevention-and-treatment. (2020).
- BioSpace . Codagenix and Serum Institute of India initiate codevelopment of a scalable, live-attenuated vaccine against the 2019 novel coronavirus, COVID-19. (2020). https://www.biospace.com/article/releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19/
- Hennessy J . Australia’s been asked to make a coronavirus vaccine at ‘unprecedented speed’. Science Alert, (2020). https://www.sciencealert.com/australian-scientists-asked-to-make-coronavirus-vaccine-at-unprecedented-speed
- Clover Biopharmaceuticals . Clover initiates development of recombinant subunit-trimer vaccine for Wuhan coronavirus (2019-ncov). (2020). https://pipelinereview.com/index.php/2020012873644/Vaccines/Clover-Initiates-Development-of-Recombinant-Subunit-Trimer-Vaccine-for-Wuhan-Coronavirus-2019-nCoV.html
- Vaxart . PipelineReview.com Vaxart announces initiation of coronavirus vaccine program. (2020). https://pipelinereview.com/index.php/2020020273689/Vaccines/Vaxart-Announces-Initiationof-Coronavirus-Vaccine-Program.html
- Inovio Pharmaceuticals . Inovio collaborating with Beijing Advaccine to advance INO-4800 vaccine against new coronavirus in China. (2020). https://www.genengnews.com/covid-19-candidates/inovio-pharmaceuticals-and-beijing-advaccine-biotechnology
- Smith J . CureVac bids to develop first mRNA coronavirus vaccine. (2020). https://www.labiotech.eu/medical/curevac-coronavirus-outbreak-cepi/
- NIH [Identifier: NCT04324606] . A study of a candidate COVID-19 vaccine (COV001). (2020). https://clinicaltrials.gov/ct2/show/NCT04324606
- ChiCTR2000030906 . A Phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector). http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000030906
- Moderna’s work on a COVID-19 vaccine candidate. (2020). https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19
- Palca J . Delivering the messenger: advances in technologies for therapeutic mRNA delivery. New England Public Media., (2020). https://www.nepm.org/post/pfizer-begins-coronavirus-vaccine-trial-us#stream/0
- NIH. [Identifier: NCT04368728] . Study to describe the safety, tolerability, immunogenicity, and efficacy of RNA Vaccine candidates against COVID-19 in healthy adults. https://clinicaltrials.gov/ct2/show/NCT04368728?term=vaccine&cond=covid-19&draw=3
- Times G . Chinese-developed inactivated COVID19 vaccine becomes first worldwide to report positive immune response. (2020) https://www.globaltimes.cn/content/1191843.shtml
- Chen W . [ChiCTR2000034780]. A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (vero cells). (2020). http://www.chictr.org.cn/showprojen.aspx?proj=56651
- China’s Sinopharm launches Phase III trial of COVID-19 vaccine in UAE. (2020). https://www.clinicaltrialsarena.com/news/sinopharm-covid-vaccine-uae-trial/
- Trialsitenews . CoronaVac moves to Phase III clinical trial in Brazil with up to 9,000 to be enrolled. (2020). https://www.trialsitenews.com/coronavac-moves-to-phase-3-clinical-trial-in-brazil-with-up-to-9000-to-be-enrolled/
- NIH [Identifier: NCT04456595] . Clinical trial of efficacy and safety of Sinovac’s adsorbed COVID-19 (inactivated) vaccine in healthcare professionals (PROFISCOV). (2020). https://clinicaltrials.gov/ct2/show/NCT04456595?term=vaccine&cond=covid-19&draw=2
- Sharma S , HindsLA. Formulation and delivery of vaccines: ongoing challenges for animal management. J. Pharm. Bioallied Sci., 4(4), 258–266 (2012).
- U.S. Food and Drug Administration . Moderna COVID-19 vaccine. FDA, (2020). https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine
- U.S. Food and Drug Administration . Pfizer-BioNTech COVID-19 vaccine. FDA, (2020). https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine
- Polack FP , ThomasSJ, KitchinNet al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med., 383(27), 2603–2615 (2020).
- Baden LR , ElSahly HM, EssinkBet al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med., 384(5), 403–416 (2021).
- Bharat Biotech . COVAXIN®, India’s indigenous COVID-19 vaccine by Bharat Biotech. (2021) https://www.bharatbiotech.com/covaxin.html
- Serum Institute of India . ChAdOx1 nCoV-19 corona virus vaccine (recombinant) COVISHIELD™. (2021). https://www.seruminstitute.com/product_covishield.php
- Carlson R . Sputnik V vaccine (2021). https://www.precisionvaccinations.com/vaccines/sputnik-v-vaccine
- Jones I , RoyP. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet, 397(10275), 642–643 (2021).
- WHO . Background document to the WHO Interim recommendations for use of Ad26.COV2.S (COVID-19) vaccine. (2021) https://apps.who.int/iris/rest/bitstreams/1336139/retrieve